PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

Sheena McCormack(MRC Clinical Trials Unit at UCL), Gita Ramjee(Perinatal HIV Research Unit), Anatoli Kamali(Uganda Virus Research Institute), Helen Rees(University of the Witwatersrand), Angela M. Crook(MRC Clinical Trials Unit at UCL), Mitzy Gafos, Ute Jentsch(University of the Witwatersrand), Robert Pool(Amsterdam University of the Arts), Maureen Chisembele(University Teaching Hospital), Saidi Kapiga(Mwanza Intervention Trials Unit), Richard Mutemwa(London School of Hygiene & Tropical Medicine), Andrew Vallely(London School of Hygiene & Tropical Medicine), Thesla Palanee‐Phillips(University of the Witwatersrand), Yuki Sookrajh(Perinatal HIV Research Unit), Charles Lacey(University of York), Janet Darbyshire(MRC Clinical Trials Unit at UCL), Heiner Grosskurth(Uganda Virus Research Institute), Albert T. Profy(Endo Pharmaceuticals (United States)), Andrew Nunn(MRC Clinical Trials Unit at UCL), Richard Hayes(London School of Hygiene & Tropical Medicine), Jonathan Weber(Imperial College London)
The Lancet
September 21, 2010
Cited by 334Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis